Enhabit, Inc. $EHAB Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. decreased its position in Enhabit, Inc. (NYSE:EHAB) by 10.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 336,072 shares of the company’s stock after selling 39,044 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.66% of Enhabit worth $2,954,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Enhabit by 295.2% during the first quarter. GAMMA Investing LLC now owns 3,533 shares of the company’s stock worth $31,000 after buying an additional 2,639 shares during the period. Group One Trading LLC raised its stake in Enhabit by 248.3% during the 4th quarter. Group One Trading LLC now owns 7,746 shares of the company’s stock valued at $60,000 after acquiring an additional 5,522 shares in the last quarter. CWM LLC boosted its position in Enhabit by 383.6% during the 1st quarter. CWM LLC now owns 11,738 shares of the company’s stock worth $103,000 after acquiring an additional 9,311 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Enhabit in the fourth quarter worth $106,000. Finally, ProShare Advisors LLC bought a new position in shares of Enhabit in the fourth quarter worth $110,000.

Enhabit Trading Down 0.3%

Shares of EHAB stock opened at $7.90 on Friday. The stock has a 50-day simple moving average of $7.57 and a 200 day simple moving average of $8.48. The stock has a market capitalization of $400.20 million, a P/E ratio of -2.96 and a beta of 1.68. Enhabit, Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $10.90. The company has a quick ratio of 1.57, a current ratio of 1.57 and a debt-to-equity ratio of 0.79.

Enhabit (NYSE:EHAB) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.10 by $0.03. Enhabit had a negative net margin of 12.84% and a positive return on equity of 2.72%. The firm had revenue of $266.10 million for the quarter, compared to analysts’ expectations of $263.39 million. On average, sell-side analysts expect that Enhabit, Inc. will post 0.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, UBS Group cut their price objective on shares of Enhabit from $10.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.67.

Insider Activity at Enhabit

In other Enhabit news, CFO Ryan Solomon bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $7.64 per share, with a total value of $76,400.00. Following the completion of the purchase, the chief financial officer directly owned 193,468 shares in the company, valued at approximately $1,478,095.52. This trade represents a 5.45% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 3.40% of the stock is owned by insiders.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.